Format

Send to

Choose Destination
Eur Respir J. 2018 Aug 16;52(2). pii: 1800537. doi: 10.1183/13993003.00537-2018. Print 2018 Aug.

QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

Author information

1
APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
2
Sorbonne Université, Université Pierre et Marie Curie 06, Unité 1135, Team E13 (Bactériologie), CR7 INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
3
Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France.
4
Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
5
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
6
Dept of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
7
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
8
Dept of Respiratory Medicine, Homerton University Hospital, London, UK.
9
Division of Clinical Infectious Diseases, Medical Clinic Research Center Borstel, German Center for Infection Research (DZIF), Clinical Tuberculosis Center, Borstel, Germany.
10
International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
11
Dept of Medicine, Karolinska Institute, Stockholm, Sweden.

Conflict of interest statement

Conflict of interest: C. Lange reports personal fees for independent lectures at sponsored symposia from Chiesi, Gilead, Abbvie, MSD, Becton Dickinson, Janssen, Lucane, Novartis and Thermofisher, outside the submitted work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center